Abstract: A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, ?-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).
Type:
Application
Filed:
November 26, 2020
Publication date:
April 27, 2023
Applicants:
RIKEN, TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES, MICROBIAL CHEMISTRY RESEARCH FOUNDATION
Inventors:
Tatsunobu SUMIYA, Yosuke NISHIGAYA, Ryosuke NAMIE, Noriaki HASHIMOTO, Akihiro ITO, Fumiyuki SHIRAI, Ko KIKUZATO, Minoru YOSHIDA
Abstract: The following are provided: a novel adenovirus vector having a shortened backbone; a nucleic acid vector expressing five or more Cas guide RNA; a nucleic acid vector containing a Cas protein-coding gene and a Cas guide RNA expression unit; a composition for genome editing containing these vectors; and a gene therapeutic method using these.
Type:
Application
Filed:
September 24, 2019
Publication date:
December 23, 2021
Applicant:
Microbial Chemistry Research Foundation
Abstract: A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.
Type:
Grant
Filed:
January 22, 2020
Date of Patent:
October 5, 2021
Assignees:
MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
Abstract: A catalyst represented by General Formula (1) below: where in the General Formula (1), R1 to R14 each independently represent a hydrogen atom or a substituent.
Type:
Grant
Filed:
August 14, 2018
Date of Patent:
April 13, 2021
Assignee:
Microbial Chemistry Research Foundation
Inventors:
Naoya Kumagai, Christopher Roderick Opie, Hidetoshi Noda, Masakatsu Shibasaki
Abstract: A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.
Type:
Application
Filed:
January 22, 2020
Publication date:
May 21, 2020
Applicants:
MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
Abstract: A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.
Type:
Grant
Filed:
July 29, 2016
Date of Patent:
April 14, 2020
Assignees:
MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
Abstract: A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.
Type:
Grant
Filed:
July 29, 2016
Date of Patent:
March 3, 2020
Assignees:
MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
Abstract: A catalyst including: neodymium; sodium; and a ligand, which is a compound expressed by Structural Formula (1) below, wherein the neodymium and the ligand form a complex at a molar ratio of 1:2 (neodymium:ligand):
Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.
Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.
Abstract: A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.
Type:
Application
Filed:
July 29, 2016
Publication date:
August 2, 2018
Applicants:
MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
Abstract: A cancer cell proliferation inhibitor including at least one selected from compounds represented by Structural Formulae (1) to (8), wherein the cancer cell is at least one of a cancer cell overexpressing a wild-type epidermal growth factor receptor and a cancer cell expressing an epidermal growth factor receptor mutant vIII.
Type:
Grant
Filed:
September 7, 2015
Date of Patent:
May 15, 2018
Assignees:
Microbial Chemistry Research Foundation, GAKUBUNKAN
Abstract: A method for producing an optically active ?-trifluoromethyl-?-amino acid derivative, the method including: allowing a compound represented by the following General Formula (1) and a compound represented by the following General Formula (2) to react in the presence of a copper-optically active phosphine complex obtained from a copper compound and an optically active phosphine compound, to thereby obtain an optically active ?-trifluoromethyl-?-amino acid derivative represented by the following General Formula (3):
Abstract: A catalyst, which is obtained by mixing a compound expressed by the following Structural Formula (1), a nitroalkane compound, a neodymium-containing compound, a sodium-containing compound, and a carbon structure:
Abstract: A compound expressed by any one of Structural Formulas (1) to (13), a method for producing the same, and a compound-containing composition, an anti-cancer agent, and an anti-Helicobacter pylori agent each containing the above compound.
Abstract: A drug combination against acid-fast bacillus, including: an inhibitor for WecA or an ortholog thereof; and at least one of an inhibitor for MurX or an ortholog thereof and an RNA synthesis inhibitor, wherein the inhibitor for WecA or an ortholog thereof is used in combination with the at least one of an inhibitor for MurX or an ortholog thereof and an RNA synthesis inhibitor; a screening method for a drug against acid-fast bacillus; and an inhibitor for WecA or an ortholog thereof.
Type:
Grant
Filed:
June 3, 2014
Date of Patent:
December 12, 2017
Assignees:
MICROBIAL CHEMISTRY RESEARCH FOUNDATION, COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Inventors:
Yoshimasa Ishizaki, Masayuki Igarashi, Patrick Joseph Brennan, Dean Calvin Crick
Abstract: A method for producing an optically active ?-trifluoromethyl-?-amino acid derivative, the method including: allowing a compound represented by the following General Formula (1) and a compound represented by the following General Formula (2) to react in the presence of a copper-optically active phosphine complex obtained from a copper compound and an optically active phosphine compound, to thereby obtain an optically active ?-trifluoromethyl-?-amino acid derivative represented by the following General Formula (3):
Type:
Application
Filed:
September 18, 2015
Publication date:
October 5, 2017
Applicant:
MICROBIAL CHEMISTRY RESEARCH FOUNDATION
Abstract: The present application provides novel compounds having anti-cancer or anti-Helicobacter pylori activity, pharmaceutical compositions and method for producing and using the novel compound.
Abstract: The present invention provides compounds belonging to 3-acyloxyindole compounds or 3-acyl-4-hydroxycoumarin compounds, a tautomer or geometric isomer thereof, or a salt thereof and methods for producing the same, which compounds are useful as antibacterial agent and as therapeutic drugs against infectious diseases.
Type:
Grant
Filed:
October 17, 2013
Date of Patent:
December 6, 2016
Assignees:
OKAYAMA UNIVERSITY, MICROBIAL CHEMISTRY RESEARCH FOUNDATION, KINKI UNIVERSITY
Abstract: A method for producing a compound represented by General Formula (1), the method including: reacting a compound represented by General Formula (3) and a compound represented by General Formula (4): where R1 and R2 each represent aliphatic group which may have substituent, or aromatic group which may have substituent (with the proviso that R1 and R2 are different groups), R3 represents aromatic group which may have substituent, and R4 represents aliphatic group which may have substituent, or aromatic group which may have substituent, where R1 and R2 each represent aliphatic group which may have substituent, or aromatic group which may have substituent (with the proviso that R1 and R2 are different groups), and R3 represents aromatic group which may have substituent, where R4 represents aliphatic group which may have substituent, or aromatic group which may have substituent.
Type:
Grant
Filed:
October 8, 2013
Date of Patent:
November 15, 2016
Assignee:
Microbial Chemistry Research Foundation
Inventors:
Masakatsu Shibasaki, Naoya Kumagai, Liang Yin, Youmei Bao